Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06671509 | Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment | PHASE1 | COMPLETED | 24 | — | — | Mar 22, 2024 | Aug 7, 2024 | Nov 4, 2024 | 1 | China |
Cmax is defined as the maximum concentration of drug
AUCinf is defined as the concentration of drug extrapolated to infinite time
AUClast is defined as the concentration of drug from time zero to the last observable concentration
Tmax is defined as the time (observed time point) of Cmax.
CL/F is defined as the apparent oral clearance following administration of the drug
Vz/F is defined as the apparent volume of distribution of the drug
| Arm | Type | Description |
|---|---|---|
| Group A: Mild Hepatic Impairment | EXPERIMENTAL | - |
| Group B: Moderate Hepatic Impairment | EXPERIMENTAL | - |
| Group C: Normal Hepatic Impairment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| YZJ-1139 | DRUG | Single oral dose, 20 mg tablet |
Inclusion Criteria: 1. Voluntarily sign an informed consent form before the start of activities related to this trial, and be able to understand the procedures and methods of this trial, willing to strictly follow the clinical trial protocol to complete this trial; 2. The subjects (including partne...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 3 | PHASE3 | Tasimelteon |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Suvorexant |
| Masimo Corporation | MASI | 1 | PHASE1 | Diprivan , Astra-Zeneca |
| Unity Health Toronto | UBX | 1 | PHASE2 | Lemborexant |
| ResMed Inc. | RMD | 1 | NA | Undisclosed |
| IQVIA Holdings Inc | IQV | 1 | — | Daridorexant, Non-orexin receptor antagonist medications for insomnia |